Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
Ruxolitinib Phase 3 Results Expected
Ruxolitinib • Myelofibrosis
Target Indication
Myelofibrosis
Clinical Trial
Last updated: 12/4/2025
KPTI
Karyopharm Therapeutics Inc.